¿Qué hay de nuevo en el diagnóstico de amiloidosis?

Marco, María A; Carretero, Marcelina; Pérez de Arenaza, Diego; Villanueva, Eugenia; Brulc, Erika B; Bendelman, Gisela; Nucifora, Elsa M; Sáez, María S; Sorroche, Patricia B; Aguirre, María A; Posadas Martínez, María L.
Rev. Hosp. Ital. B. Aires (En línea) ; 43(4): 209-213, dic. 2023.
Artículo en Español | LILACS, UNISALUD, BINACIS | ID: biblio-1537564

Documentos relacionados

  1. [Difficulties in differential diagnosis of the AL- and ATTR-cardiac amyloidosis. Case report].
  2. Glaucoma is probably not useful as a red flag for amyloidosis.
  3. Validation of an Artificial Intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis polyneuropathy as a key example.
  4. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
  5. Changes in nerve conduction studies predate clinical symptoms onset in early onset Val30Met hereditary ATTR amyloidosis.
  6. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
  7. Emerging Therapies for Transthyretin Amyloidosis.
  8. [A rare variant in the TTR gene (p.E112K) is associated with systemic amyloidosis and a new symptom - skin hyperemia in response to ethanol intake: family segregation analysis, literature review, and a clinical case. Case report].
  9. Can we identify hereditary TTR amyloidosis by the screening of carpal tunnel syndrome patients?
  10. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?